Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
Bell
Ian M
IM
Merck Research Laboratories, WP14-2, P.O. Box 4, Sumneytown Pike, West Point, PA 19486, USA. ian_bell@merck.com
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015195:Drug Design; D051231:Farnesyltranstransferase; D011905:Genes, ras / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase